These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 35454137)

  • 1. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
    Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
    Kamath D; Iwakuma T; Bossmann SH
    Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should mutant TP53 be targeted for cancer therapy?
    Wang Z; Strasser A; Kelly GL
    Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
    Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
    J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.
    Zhu J; Sammons MA; Donahue G; Dou Z; Vedadi M; Getlik M; Barsyte-Lovejoy D; Al-awar R; Katona BW; Shilatifard A; Huang J; Hua X; Arrowsmith CH; Berger SL
    Nature; 2015 Sep; 525(7568):206-11. PubMed ID: 26331536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
    Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
    Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor p53 and its gain-of-function mutants in cancer.
    Liu J; Zhang C; Feng Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the Role of
    Li W; Li L; Yang H; Shi C; Lei Z; Guo L; Wang Y
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):272. PubMed ID: 39082342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53: it's not all one and the same.
    Kennedy MC; Lowe SW
    Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
    Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
    Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
    Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
    Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion-like aggregation of mutant p53 in cancer.
    Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
    Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.